Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type

By sjmartinez • November 12, 2023

Alexis AF, Silverberg JI, Rice ZP, Armstrong AW, Desai SR, Fonacier L, Kabashima K, Biswas P, Cella RR, Chan GL, Levenberg M. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. 2023 Nov 8:S1081-1206(23)01394-7. doi: 10.1016/j.anai.2023.11.002. Epub ahead of print. PMID: 37949351.

Tags: abrocitinib, atopic eczema, Clinical Trial, Dermatology, Ethnicity, Publications, Race

Complete genomes of the hydrogenotrophic methanogen species -Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1

Humm E, Chettiyar R, Rubbi L, Del Vecchio G, Pellegrini M, Ha SM, Gunsalus RP. Complete genomes of the hydrogenotrophic methanogen species-Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1.[...]

SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement

Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J,[...]

A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the Dermatology Match Process

D'Amiano AJ, Rohr B, Glick B, Hogeling M, Keller M, Sunshine J. A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the[...]